PEPFAR News and Research

RSS

Safety of AIDS drug to prevent mother-to-child transmission of HIV questioned

In light of several recent drug industry scandals roiling the nation's public health and raising serious questions about the US bodies that license and regulate the industry -- and startling new revelations today concerning National Institutes of Health (NIH) officials and the safety of a brand name AIDS drug used to prevent mother-to-child transmission of the HIV

14 Dec 2004

FDA Vioxx fiasco raises questions about AIDS drug approvals for developing world

AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.

19 Nov 2004

AIDS Healthcare Foundation, AIDS Therapeutic Treatment Now Coalition to unveil ambitious pledge at Bangkok 2004

Plans for advocacy, activism and protests throughout the weeklong AIDS conference to highlight the pressing need for increased access to life-saving anti-retroviral therapy (ARV) worldwide.

8 Jul 2004

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries

25 Jun 2004

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries, according to the Pan American Health Organization (PAHO).

15 Jun 2004

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products.

16 May 2004